(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






5 Result: Chevron

Market Buzz: Phillips 66 and Chevron Post Mixed Results

October 27th, 2023

Phillips 66 (NYSE: PSX) reported its third-quarter 2023 earnings, with a figure of $4.63 per share. However, this result fell short of the consensus EPS estimate of $4.76. On the revenue side, the company performed better, with quarterly sales reachi. Read more

Energy Titans Exxon Mobil, Chevron, and Xcel Energy Earnings On Deck

October 22nd, 2023

On Friday, October 27, a lineup of major companies is set to unveil their financial results, including: Exxon Mobil Corporation (NYSE: XOM), a prominent player in the energy industry, is scheduled to release its financial results for the third qua. Read more

Potential $3M Deal Boosts SuperCom; Bullish View On Chevron

August 16th, 2023

Shares of SuperCom Ltd. (Nasdaq: SPCB) jumped over 5% in pre-market trading following the announcement of a new contract for Alcohol Monitoring technologies and services in California. The contract, spanning an initial 3-year term, involves per-un. Read more

Chevron, Nevro, America Movil, Hillman Solutions, Grupo Televisa, and ACNB - Assessing Potential Upside and Price Targets

May 31st, 2023

Chevron Corporation (NYSE: CVX), a multinational energy corporation, has been upgraded from Underweight to Neutral by JP Morgan. The price target for $CVX has also been raised from $161 to $170 based on the firm's view.  On Wednesday, $CVX cl. Read more

Freeline Therapeutics Receives Innovation Passport for Gaucher Disease Drug; Rain Oncology's Clinical Trial Disappoints; Chevron Expands with PDC Energy Acquisition

May 22nd, 2023

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) has made an important announcement regarding its drug FLT201. The company revealed that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease type 1 under the Innovative. Read more

Load More Content